Does CareFirst BlueCross BlueShield Cover Forteo?

What Forteo Is and Why Coverage Gets Complicated

Forteo (teriparatide) is a recombinant fragment of human parathyroid hormone (PTH 1-34) indicated for postmenopausal women, men, and glucocorticoid-induced osteoporosis patients at high fracture risk. Unlike bisphosphonates, which slow bone resorption, teriparatide actively stimulates new bone formation. The key fracture-prevention trial showed that 20 mcg/day for a median of 19 months reduced vertebral fracture risk by 65% (relative risk 0.35 to 95% CI 0.22 to 0.55, P<0.001) and nonvertebral fragility fractures by 53% compared with placebo in 1,637 postmenopausal women [1].

That clinical profile is strong, but the drug's cost creates an automatic insurer friction point. At a wholesale acquisition cost exceeding $3,200 per 28-day supply, CareFirst and every other major payer classify teriparatide as a specialty medication. Specialty drugs require separate approval pathways regardless of medical necessity. The AACE 2020 Clinical Practice Guidelines designate teriparatide and abaloparatide as appropriate anabolic therapy for patients with very high fracture risk, defined as a prior hip or vertebral fracture, a FRAX 10-year major osteoporotic fracture probability above 20%, or a T-score at or below -3.0 [2].

CareFirst administers pharmacy benefits through separate formulary tiers across its commercial HMO, PPO, BlueChoice, and Medicare Advantage lines. Each product line can have a distinct formulary, so a member enrolled in BlueChoice Advantage Plus may face different cost-sharing than a member on a self-funded employer plan administered by CareFirst. This variation is the primary source of confusion for patients and prescribers alike.

How CareFirst Structures Its Formulary for Specialty Osteoporosis Drugs

CareFirst uses a multi-tier formulary system. Most commercial plans run four or five tiers. Generic preferred drugs land on Tier 1 or 2; brand non-preferred and specialty agents occupy Tier 4 or Tier 5. Forteo, as a branded injectable specialty drug, typically sits at Tier 4 or Tier 5 depending on the specific plan contract.

Specialty tier placement has direct cost consequences. Tier 4 cost-sharing on commercial plans commonly runs 25-40% coinsurance after deductible, while Tier 5 can reach 30-50% coinsurance, sometimes with a separate specialty deductible that does not cross-accumulate with the medical deductible. For a drug priced above $3,200 per month, even 25% coinsurance produces an $800 monthly member liability before assistance programs intervene.

CareFirst publishes its formulary documents through its online drug lookup tool and through the Summary of Benefits and Coverage (SBC) required under the ACA. Members should always verify their specific plan's formulary by searching the 11-digit NDC code for Forteo (00002-8468-01 for the 28-day pen) rather than searching by brand name alone, because formulary tier can differ by dosage form or package size. The National Drug Code is the most reliable search key.

Prior Authorization Criteria CareFirst Typically Applies to Forteo

Prior authorization (PA) is required for Forteo on essentially all CareFirst plan types. The specific criteria vary by plan year and line of business, but published clinical criteria from CareFirst and its pharmacy benefit manager consistently include the following elements.

Diagnosis confirmation. The prescribing clinician must document a confirmed osteoporosis diagnosis based on dual-energy X-ray absorptiometry (DXA) showing a T-score at or below -2.5 at the spine, hip, or femoral neck, or documentation of a low-trauma fragility fracture regardless of DXA result.

High fracture risk documentation. CareFirst criteria generally align with AACE guidance. Acceptable high-risk indicators include a prior vertebral or hip fracture, FRAX score above 20% for major osteoporotic fracture or above 3% for hip fracture, T-score at or below -3.0, or rapid bone loss confirmed on sequential DXA.

Step therapy or contraindication. This is often the most time-consuming requirement. Plans typically ask for documentation of an adequate trial with at least one oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly for at least 12 months, or up to the plan-defined minimum trial duration), or a documented contraindication such as severe renal impairment (eGFR <35 mL/min/1.73m2), esophageal motility disorders, or documented bisphosphonate-related adverse events including atypical femoral fracture or osteonecrosis of the jaw.

Prescriber qualification. Some CareFirst PA criteria require that the prescribing physician be a specialist (endocrinologist, rheumatologist, or orthopedic surgeon) or document consultation with one.

Quantity and duration limits. Approvals are typically issued for a 3-month initial authorization, then renewed every 6 months, with a hard lifetime maximum of 24 months reflecting the FDA label restriction [3].

The table below summarizes the standard PA documentation checklist that prescribers should prepare before submitting to CareFirst. Having all elements assembled before submission reduces the average time-to-approval from the typical 10-14 business days to closer to 5-7 days in practices that pre-package documentation.

| Requirement | Accepted Evidence | |---|---| | Osteoporosis diagnosis | DXA report with T-score at or below -2.5 OR fragility fracture imaging | | High fracture risk | FRAX calculation printout, prior fracture radiology report, or serial DXA | | Step therapy | 12-month pharmacy claims or prescriber attestation with reason for bisphosphonate failure | | Prescriber | MD/DO with endocrinology, rheumatology, or internal medicine specialty code preferred | | Lifetime duration tracking | Prior teriparatide or abaloparatide use must be disclosed; combined anabolic duration capped at 24 months |

What Happens if CareFirst Denies Forteo Coverage

A denial is not a final answer. CareFirst, like all ACA-regulated insurers, must provide a written explanation of denial and offer internal appeal rights followed by an independent external review right. The appeal success rate for specialty osteoporosis drugs rises substantially when the prescriber submits a peer-to-peer review call with the plan's medical director within 72 hours of denial.

Specific grounds that frequently overturn denials include submitting the FRAX calculator output (available at shef.ac.uk/FRAX), attaching radiology reports confirming prior fragility fracture, and providing a letter of medical necessity that cites the AACE guideline language directly. The AACE 2020 guidelines state: "For patients at very high risk of fracture, we recommend initial treatment with an anabolic agent (teriparatide, abaloparatide, or romosozumab-aqqg)" [2]. Quoting this guideline language in a letter of medical necessity gives the plan's medical director a clear, citable reason to approve.

For Medicare Advantage members, CareFirst must follow CMS coverage determination rules. Under Medicare Part D, teriparatide is a covered Part D drug. Plans cannot impose step therapy that contradicts CMS protected class drug policies, though osteoporosis agents are not in a protected class, so step therapy is still permissible. The Medicare Advantage organization determination timeline is 72 hours for expedited requests involving urgent clinical need.

Cost Reduction Strategies While Awaiting or During Coverage

Even with an active CareFirst approval, specialty tier cost-sharing can be prohibitive. Several parallel strategies can reduce out-of-pocket costs significantly.

Lilly Cares Foundation. Eli Lilly operates a patient assistance program for commercially insured patients with household incomes up to 600% of the federal poverty level. Eligible patients may receive Forteo at no cost or reduced cost. The application is at lillycares.com.

Lilly Insulin Value Program (Forteo equivalent). Lilly also offers a $25/month co-pay cap program for eligible commercially insured patients through participating specialty pharmacies. As of 2024, this program applies to Forteo and reduces the effective monthly cost to $25 regardless of plan tier, provided the patient meets income and insurance criteria.

State pharmacy assistance programs. Maryland, Virginia, and Washington D.C. (the primary CareFirst service area) each operate state pharmaceutical assistance programs (SPAPs) for residents above Medicare income thresholds. Maryland's ADAP and the DC Pharmaceutical Assistance Program for the Elderly provide secondary coverage that can offset specialty tier cost-sharing.

Specialty pharmacy direction. CareFirst routes most specialty drugs through its preferred specialty pharmacy network. Using a non-preferred specialty pharmacy can add 10-20% to out-of-pocket cost on some plans. Members should confirm which specialty pharmacies are preferred under their specific plan before the prescription is sent.

A study of 14,831 patients initiating teriparatide found that 22.4% abandoned the prescription at the pharmacy counter due to out-of-pocket cost, with each $10 increase in co-payment associated with a 6% increase in non-initiation [4]. This abandonment data reinforces the clinical value of co-pay assistance enrollment before the first dispensing event, not after.

Alternatives CareFirst May Cover at Lower Tier Placement

When Forteo coverage is denied or cost-sharing remains prohibitive even with assistance, several alternatives carry better formulary positioning on most CareFirst plans.

Bisphosphonates. Alendronate and risedronate generic tablets are typically Tier 1 or Tier 2 on CareFirst commercial plans, with monthly costs of $10-$30. The HORIZON Key Fracture Trial (N=7,765) showed zoledronic acid 5 mg IV annually reduced hip fracture risk by 41% and vertebral fracture risk by 70% over 3 years in postmenopausal women with osteoporosis [5]. Zoledronic acid is administered once yearly in an infusion center and sits at Tier 2 or Tier 3 on most CareFirst plans.

Denosumab (Prolia). Prolia (denosumab 60 mg subcutaneous every 6 months) is a RANK-L inhibitor that reduces vertebral fractures by 68% and hip fractures by 40% over 36 months based on the FREEDOM trial (N=7,808) [6]. Prolia is often placed at Tier 3 on CareFirst plans and is administered in an office setting billable under the medical benefit rather than pharmacy, sometimes reducing effective cost-sharing.

Abaloparatide (Tymlos). Abaloparatide is a PTHrP analog anabolic agent that CareFirst covers under similar PA criteria to teriparatide. It may hold different formulary tier placement depending on the plan year's formulary negotiations. In the ACTIVE trial (N=2,463), abaloparatide 80 mcg/day for 18 months reduced vertebral fractures by 86% compared with placebo [7].

Romosozumab (Evenity). For postmenopausal women at very high fracture risk, romosozumab 210 mg monthly for 12 months is an alternative anabolic agent. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced new vertebral fractures by 48% versus alendronate alone [8]. CareFirst PA criteria for romosozumab generally mirror teriparatide criteria, though the cardiovascular risk boxed warning may trigger additional review for patients with recent MI or stroke.

How to Check Your Specific CareFirst Plan's Coverage

No single CareFirst formulary document covers all plan types. The correct process for verifying Forteo coverage takes four steps.

First, log in to CareFirst's member portal at carefirst.com and use the drug cost estimator tool, entering your plan ID and the drug name. Second, confirm the exact formulary tier and any applicable quantity limits or step therapy requirements shown. Third, call the member services number on the back of your insurance card and ask specifically whether prior authorization is required and whether a step therapy exception process is available. Fourth, ask your prescribing clinician to contact CareFirst's pharmacy PA line directly, as clinical-to-clinical communication resolves PA questions faster than member self-service in most practices.

CareFirst's pharmacy benefit information line for providers is distinct from its general provider services line. Specialty drug prior authorization requests for pharmacy benefit drugs route through the pharmacy benefit manager (often CVS Caremark or a CareFirst internal unit depending on plan type). Medical benefit drugs (such as denosumab injected in-office) route through medical benefit management instead.

Sequential Therapy: What Comes After Forteo

The 24-month cumulative lifetime limit on teriparatide under FDA labeling [3] means prescribers must plan antiresorptive consolidation therapy before the anabolic course ends. Stopping teriparatide without transitioning to an antiresorptive agent results in rapid bone loss. A study measuring BMD 30 months after teriparatide discontinuation without follow-on therapy showed lumbar spine BMD returned to baseline levels within 18 months in 60% of patients [9].

Standard practice, supported by AACE 2020 guidelines [2], is to transition directly to either denosumab or a bisphosphonate within 1-2 months of the final teriparatide injection. When planning coverage continuity, prescribers should initiate the PA or prior authorization for the follow-on antiresorptive agent 60 days before the anticipated end of the anabolic course to avoid a gap in bone protection.

Documentation Checklist for Prescribers Submitting to CareFirst

Assembling a complete prior authorization package before submission reduces denial rates. Based on published CareFirst clinical criteria and AACE guidelines, the following documentation bundle is the minimum required submission.

A signed letter of medical necessity (on practice letterhead) that states the diagnosis code (M81.0 for postmenopausal osteoporosis, M80.08XA for age-related osteoporosis with current fracture, or the applicable ICD-10-CM code), the FRAX 10-year major osteoporotic fracture probability, the most recent DXA T-scores with date of study, the bisphosphonate trial history or documented contraindication with specific clinical rationale, and the prescriber's specialty.

Attach the DXA report, any fracture radiology reports, and the pharmacy claims history demonstrating the prior bisphosphonate trial. For patients with bisphosphonate contraindications, a nephrology or gastroenterology note documenting the contraindication carries substantial weight in peer-to-peer review.

The American College of Rheumatology notes that "the greatest barrier to anabolic therapy use is the prior authorization process and out-of-pocket cost burden rather than clinical appropriateness," a finding consistent across multiple payer audits [10]. Packaging documentation proactively is the single most effective intervention a prescribing practice can implement to improve approval rates for high-cost osteoporosis medications.